Airway gene expression identifies subtypes of type 2 inflammation in severe asthma

Background Type 2 inflammation is characterized by enhanced activity of interleukin (IL)‐4, ‐5 and ‐13, and treatments targeting these pathways are available for treatment of severe asthma. At present, the pattern of pathway activity and the implications overlapping of pathway activity are unknown....

Full description

Saved in:
Bibliographic Details
Published in:Clinical and experimental allergy 2022-01, Vol.52 (1), p.59-69
Main Authors: Frøssing, Laurits, Silberbrandt, Alexander, Von Bülow, Anna, Kjærsgaard Klein, Ditte, Ross Christensen, Marcus, Backer, Vibeke, Baines, Katherine J., Porsbjerg, Celeste
Format: Article
Language:English
Subjects:
Adrenal Cortex Hormones - therapeutic use
Asthma
Asthma - diagnosis
Asthma - drug therapy
Asthma - genetics
Cluster analysis
Corticosteroids
CXCR2 protein
Gene Expression
Helper cells
Humans
IL-1β
Inflammation
Inflammation - metabolism
Interleukin 1
Kinases
Lymphocytes T
Patients
Respiratory tract
Sputum
Sputum - metabolism
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Type 2 inflammation is characterized by enhanced activity of interleukin (IL)‐4, ‐5 and ‐13, and treatments targeting these pathways are available for treatment of severe asthma. At present, the pattern of pathway activity and the implications overlapping of pathway activity are unknown. Objective We hypothesized that clustering of airway mRNA expression would identify distinct molecular subtypes of severe asthma and thereby uncover the prevalence and overlap of pathway activity. Methods Sputum mRNA expression of genes related to expression of IL‐5(CLC, CPA3 and DNASE1L3), IL‐13(IL13Ra1, TNFSF14 and SERPINB2), T1/Th17 activity(IL1B, ALPL and CXCR2) and in vitro response to corticosteroids (FKBP512) and mepolizumab (ARAP3) was analysed in patients (n = 109) with severe asthma and healthy controls (n = 22). A cluster analysis of gene expression was performed. The response to a short course of OCS was assessed in a subset of patients (n = 29). Results Five molecular clusters were identified. Three had abundant T2 gene expression of which two (n = 39 and n = 9) were characterized by abundant expression of both IL‐13‐ and IL‐5‐related genes. The last (n = 6) had only abundant IL‐5‐related gene expression. These T2‐high molecular clusters could not be distinguished using T2 biomarkers. T2‐ and Th1/Th17‐related mRNA expression were co‐expressed across all clusters. OCS significantly reduced T2 gene expression (CLC, IL13Ra1, SERPINB2 and ARAP3) and significantly increase expression of Th1/Th17‐related genes (ALPL and CXCR2). Conclusions and clinical relevance Clustering of airway mRNA expression identified five molecular clusters of severe asthma of which three were considered T2 high. Co‐expression of IL‐5‐ and IL‐13‐related genes at moderate levels was present in almost half of patients, while marked elevated expression of both was rare. In contrast to IL‐5, clusters with isolated IL‐13‐ and Th1/Th17‐related gene expression were not identified.
ISSN:0954-7894
1365-2222
DOI:10.1111/cea.13966